Medicaid Rebate Extension To Territories Operationally, Legally Questionable, Manufacturers Say
This article was originally published in The Pink Sheet Daily
Executive Summary
Manufacturers strongly oppose a CMS proposal that would extend the manufacturer drug rebate program to include drugs sold to Medicaid enrollees in Puerto Rico, Virgin Islands, Guam, Northern Mariana Islands and American Samoa.
You may also be interested in...
Drug Shortage Rules Surface In Latest FDA Regulatory Agenda
FDA has yet to prognosticate on a schedule for other FDASIA-mandated regulations; HHS says that FDA’s priorities for the coming year will involve devices and food, as well as promoting international regulatory cooperation.
Calculating AMP: Medicaid Proposed Rule Provides Answers, Some Detailed, Some Vague, To Manufacturers’ Questions
Manufacturers seeking answers on how to comply with the law on calculating average manufacturer price for drugs in Medicaid can turn to CMS’ proposed rule on the topic, published in the Feb. 2 Federal Register. The rule addresses a wide range of issues, including how closely manufacturers must track sales to retail community pharmacies for reporting, how to define a “retail community pharmacy,” how to define “bona fide service fees” and fair market value for them, since they can be excluded from AMP, and how to identify “5i” specialty drugs not generally dispensed at a retail community pharmacy, since they have their own special rules for calculating AMP.
GSK's Nucala Is Significantly Overpriced, ICER Draft Report Finds
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.